These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9327904)

  • 1. Therapeutic actions of L-deprenyl in dogs: a model of human brain aging.
    Ruehl WW; Neilson J; Hart B; Head E; Bruyette DS; Cummings BJ
    Adv Pharmacol; 1998; 42():316-9. PubMed ID: 9327904
    [No Abstract]   [Full Text] [Related]  

  • 2. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease.
    Thomas T
    Neurobiol Aging; 2000; 21(2):343-8. PubMed ID: 10867219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine oxidase inhibitors and their pharmacological significance.
    Sandler M
    Acta Neurol Scand Suppl; 1983; 95():37-41. PubMed ID: 6428147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antioxidants and Alzheimer's disease: time to stop feeding vitamin E to dementia patients?
    Ames D; Ritchie C
    Int Psychogeriatr; 2007 Feb; 19(1):1-8. PubMed ID: 17310512
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline).
    Riederer P; Jellinger K
    Acta Neurol Scand Suppl; 1983; 95():43-55. PubMed ID: 6145282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geroprotection in the future. In memoriam of Joseph Knoll: The selegiline story continues.
    Ferdinandy P; Yoneda F; Muraoka S; Fürst S; Gyires K; Miklya I
    Eur J Pharmacol; 2020 Feb; 868():172793. PubMed ID: 31743738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of canine pituitary-dependent hyperadrenocorticism with l-deprenyl (Anipryl).
    Bruyette DS; Ruehl WW; Entriken T; Griffin D; Darling L
    Vet Clin North Am Small Anim Pract; 1997 Mar; 27(2):273-86. PubMed ID: 9076907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.
    Higuchi H; Kamata M; Sugawara Y; Yoshida K
    Clin Neuropharmacol; 2005; 28(4):191-2. PubMed ID: 16062100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
    Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
    J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose regimen of deprenyl (selegiline) and platelet MAO activities.
    Oreland L; Johansson F; Ekstedt J
    Acta Neurol Scand Suppl; 1983; 95():87-9. PubMed ID: 6428150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.
    Berry MD; Juorio AV; Paterson IA
    Prog Neurobiol; 1994 Oct; 44(2):141-61. PubMed ID: 7831475
    [No Abstract]   [Full Text] [Related]  

  • 12. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of pituitary-dependent hyperadrenocorticism in dogs: should L-deprenyl (Anipryl) ever be used?
    Peterson ME
    J Vet Intern Med; 1999; 13(4):289-90. PubMed ID: 10449217
    [No Abstract]   [Full Text] [Related]  

  • 14. [Monoamine oxidase inhibitors: prospects for the use in clinical practice].
    Evtushenko SK; Lutskiĭ IS; Efimenko VN; Kazarian NE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(8):53-60. PubMed ID: 12233260
    [No Abstract]   [Full Text] [Related]  

  • 15. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment.
    Roesler R; Quevedo J; Walz R; Bianchin M
    Neurology; 1999 Jun; 52(9):1920-1. PubMed ID: 10371554
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment.
    Di Rocco A
    Neurology; 1999 Jun; 52(9):1920; author reply 1920-1. PubMed ID: 10371553
    [No Abstract]   [Full Text] [Related]  

  • 18. MAO-B inhibition by a single dose of l-deprenyl or lazabemide does not prevent neuronal damage following focal cerebral ischaemia in rats.
    Jolkkonen J; Kauppinen R; Nyman L; Haapalinna A; Sivenius J
    Pharmacol Toxicol; 2000 Nov; 87(5):242-5. PubMed ID: 11129505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline's neuroprotective capacity revisited.
    Riederer P; Lachenmayer L
    J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
    [No Abstract]   [Full Text] [Related]  

  • 20. L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia.
    Knollema S; Aukema W; Hom H; Korf J; ter Horst GJ
    Stroke; 1995 Oct; 26(10):1883-7. PubMed ID: 7570743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.